Innovative oncolytic viruses (OVs) resulting from this collaboration will use Transgene's proprietary next generation viral platform Invir.IOTM in which one or more of Randox's SdAbs (single- domain antibodies) will be vectorized. TRANSGENE AND RANDOX DEVELOP OV'S FOR SOLID TUMORS During DA appe...